These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35848693)

  • 1. Information on migraine drugs in commonly available Indian drug information sources - Whether we satisfied the community needs?
    Thangaraju P; Mahesh K; Venkatesan S
    Indian J Pharmacol; 2022; 54(3):216-220. PubMed ID: 35848693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rational migraine management: optimising treatment with the triptans.
    Millson DS
    Funct Neurol; 2000; 15 Suppl 3():182-91. PubMed ID: 11200789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rizatriptan: a pharmacoeconomic review of its use in the acute treatment of migraine.
    McCormack PL; Foster RH
    Pharmacoeconomics; 2005; 23(12):1283-98. PubMed ID: 16336021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot in the acute treatment of migraine.
    Zhang L; Hay JW
    CNS Drugs; 2005; 19(7):635-42. PubMed ID: 15984898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimigraine drugs.
    Diener HC; Kaube H; Limmroth V
    J Neurol; 1999 Jul; 246(7):515-9. PubMed ID: 10463349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy.
    Tfelt-Hansen P; De Vries P; Saxena PR
    Drugs; 2000 Dec; 60(6):1259-87. PubMed ID: 11152011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of use of triptans and reasons for switching them in a tertiary care migraine population.
    Sheftell FD; Feleppa M; Tepper SJ; Volcy M; Rapoport AM; Bigal ME
    Headache; 2004; 44(7):661-8. PubMed ID: 15209687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coronary side-effect potential of current and prospective antimigraine drugs.
    MaassenVanDenBrink A; Reekers M; Bax WA; Ferrari MD; Saxena PR
    Circulation; 1998 Jul; 98(1):25-30. PubMed ID: 9665056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of rizatriptan and other triptans on stringent measures of efficacy.
    Adelman JU; Lipton RB; Ferrari MD; Diener HC; McCarroll KA; Vandormael K; Lines CR
    Neurology; 2001 Oct; 57(8):1377-83. PubMed ID: 11673575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials.
    Ferrari MD; Goadsby PJ; Roon KI; Lipton RB
    Cephalalgia; 2002 Oct; 22(8):633-58. PubMed ID: 12383060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Migraine pharmacotherapy with oral triptans: a rational approach to clinical management.
    Millson DS; Tepper SJ; Rapoport AM
    Expert Opin Pharmacother; 2000 Mar; 1(3):391-404. PubMed ID: 11249525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy.
    Villalón CM; Centurión D; Valdivia LF; De Vries P; Saxena PR
    Proc West Pharmacol Soc; 2002; 45():199-210. PubMed ID: 12434581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug dependence associated with triptans and ergot derivatives: a case/non-case study.
    Beau-Salinas F; Jonville-Béra AP; Cissoko H; Bensouda-Grimaldi L; Autret-Leca E
    Eur J Clin Pharmacol; 2010 Apr; 66(4):413-7. PubMed ID: 20024536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Difference in described indications of medicines among drug information sources in India: An issue urgently to be addressed.
    Singh H; Mohan P; Kumar R; Gupta YK
    J Nat Sci Biol Med; 2016; 7(1):93-7. PubMed ID: 27003979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of antimigraine compounds on cognitive processing: a placebo-controlled crossover study.
    Evers S; Rüschenschmidt J; Frese A; Rahmann A; Husstedt IW
    Headache; 2003; 43(10):1102-8. PubMed ID: 14629247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rizatriptan: an update of its use in the management of migraine.
    Wellington K; Plosker GL
    Drugs; 2002; 62(10):1539-74. PubMed ID: 12093318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spotlight on rizatriptan in migraine.
    Wellington K; Jarvis B
    CNS Drugs; 2002; 16(10):715-20. PubMed ID: 12269863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ergotamine and dihydroergotamine: a review.
    Bigal ME; Tepper SJ
    Curr Pain Headache Rep; 2003 Feb; 7(1):55-62. PubMed ID: 12525272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dihydroergotamine, ergotamine, methysergide and sumatriptan - basic science in relation to migraine treatment.
    Dahlöf C; Maassen Van Den Brink A
    Headache; 2012 Apr; 52(4):707-14. PubMed ID: 22444161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of rizatriptan and other triptans on the nausea symptom of migraine: a post hoc analysis.
    Lipton RB; Pascual J; Goadsby PJ; Massiou H; McCarroll KA; Vandormael K; Jiang K; Lines CR
    Headache; 2001 Sep; 41(8):754-63. PubMed ID: 11576198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.